Newamsterdam Pharma Company N V (NAMS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Newamsterdam Pharma Company N v   (NASDAQ: NAMS)


Newamsterdam Pharma N V's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Newamsterdam Pharma N V's ROI in the second quarter of 2026?
Newamsterdam Pharma Company N V recorded a cumulative net loss of $-260 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -38.27%.

Within the Healthcare sector 404 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2080 to 3470.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -0.22 % 22.39 % 50.04 % 100.19 % 73.65 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 631 665 683 732 781
Return On Investment (TTM) -38.27 % -29.74 % -27.37 % -31.15 % -26.84 %
NAMS's Overall Ranking # 3470 # 2080 # 3139 # 3286 # 0
Seq. Investment Change TTM -5.22 % -3.92 % -2.43 % 12.3 % 16.25 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -260 -213 -204 -238 -182

NAMS Company Profile >> Back to NAMS Roi Comparisons >> See Annual NAMS Return On Investment



Return On Investment NAMS's Ranking
Within: No.
Industry # 160
Sector # 405
Overall # 3470

Return On Investment Statistics
High Average Low
-27.37 %
-31.63 %
-38.27 %
(Dec 31 2025)   (Jun 30 2026)



  News about Newamsterdam Pharma Company N v Return on Investment ROI

NewAmsterdam Pharma Seeks Recovery Amid Financial Losses and Promising Clinical Trials for Obicetrapib,

January 10, 2025

NewAmsterdam Pharma Looks Forward Amidst Financial Losses and Promising Cardiovascular ResearchBy CSI MarketAs NewAmsterdam Pharma Company N.V. strides into 2025, the company s ambitions remain remarkably high despite the turbulence reflected in its recent financial performance. With a reported cumulative net loss of $133 million by the third quarter of 2024 and a striking negative return on investment (ROI) of -34.83%, the outlook for the innovative pharmaceutical company is a mix of promise and concern.The key driver of NewAmsterdam s optimism lies in obicetrapib, their flagship oral, non-statin lipid-lowering therapy, which is at the forefront of clinical trials intended to tackle one of the most pressing challenges in modern medicine: cardiovascular disease (CVD). As the world grapples with rising rates of atherosclerosis, NewAmsterdam s work in this area could provide a much-needed breakthrough for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C) levels.





Financial Statements
Newamsterdam Pharma N V's II. Quarter Investments $ 631 Millions NAMS's Balance sheet
Newamsterdam Pharma N V's II. Quarter Income $ -64 Millions Quarterly NAMS's Income Statement
NAMS's Income by Division See NAMS's Income by Division


NAMS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022
Total Investments in Millions 683 758 297 442 0
Y / Y Investment Growth -9.78 % 154.88 % -32.82 % - -
Net Income in Millions -204 -242 -177 -23 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -29.82 % -31.89 % -59.53 % -5.12 % -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NAMS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NAMS's Competitors
Subscribers only: Roi for Newamsterdam Pharma N V's Suppliers
Subscribers only: Return On Investment for NAMS's Customers

Other Ratios
NAMS's Roa NAMS's Inventory Turnover Ratio NAMS's Growth Rates NAMS's Dividend Statistics
NAMS's Profitability Ratios NAMS's Asset Turnover Ratio NAMS's Dividend Growth
NAMS's Roe NAMS's Valuation Ratios NAMS's Financial Strength Ratios NAMS's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-11T10:07:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.